Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250372) titled 'A study to investigate the safety and preliminary efficacy of GSK5460025 alone or in combination with other anti-cancer agents in participants with solid tumors' on Oct. 3.
Study Type: Interventional
Study Design:
single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
Primary Sponsor: Ishibashi Hideyasu
Condition:
dMMR/MSI-H, advanced solid tumors
Intervention:
GSK5460025 will be administered
In Part 1 (Dose Escalation), GSparticipants will receive a single lead-in dose of GSK5460025 followed by a 1-week (7 day) washout period before starting repeat dosing. ...